| Delta Physical Therapy And Sports | |
|
95 White Sage Ave, Suite C, Delta, UT 84624-5555 | |
| (435) 864-2551 | |
| (435) 864-3573 |
| Full Name | Delta Physical Therapy And Sports |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 95 White Sage Ave, Delta, Utah |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801834700 | NPI | - | NPPES |
| 1669788725 | Medicaid | UT | |
| 529299099026 | Medicaid | UT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 285712-2401 (Utah) | Primary |
| 225X00000X | Occupational Therapist | 5530573-4201 (Utah) | Secondary |
| Provider Name | Louis Howard Quackenbush |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1487780003 PECOS PAC ID: 1850292285 Enrollment ID: I20040127000421 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Randy D Stinson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669788725 PECOS PAC ID: 3375732068 Enrollment ID: I20110111000913 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Scott R Allen |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1467865840 PECOS PAC ID: 4486931086 Enrollment ID: I20170509001641 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Andrew M Wankier |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1235634569 PECOS PAC ID: 7315290053 Enrollment ID: I20181027000036 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Dustin Kunz |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1235779224 PECOS PAC ID: 9931538337 Enrollment ID: I20200407000222 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Katy Glenn Roper |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1477162048 PECOS PAC ID: 9739506080 Enrollment ID: I20200901001062 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Provider Name | Mylisa Jacobson |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1245980176 PECOS PAC ID: 4284020645 Enrollment ID: I20220412000532 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Delta Physical Therapy And Sports 95 White Sage Ave, Suite C, Delta, UT 84624-5555 Ph: (435) 864-2551 | Delta Physical Therapy And Sports 95 White Sage Ave, Suite C, Delta, UT 84624-5555 Ph: (435) 864-2551 |
News Archive
The Redwood Gazette recently reported that there is "hopeful news" for patients who are struggling financially and worried about paying for their medicines. The Partnership for Prescription Assistance (PPA) has helped more than 6 million patients find programs providing prescription medicines for free or nearly free.
Bedwetting perennially drives parents to the pediatric urology clinic at Johns Hopkins Children's Center, but September — and the start of the school year — always brings a predictable uptick in visits, according to pediatric urologist Ming-Hsien Wang, M.D.
Medtronic, Inc. today announced that it has entered into an exclusive distribution agreement with Miami Instruments, LLC - a company focused on the design of innovative surgical instruments for minimally invasive cardiac surgery procedures - and has introduced the company's first two products in the U.S.
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Pharmasset, Inc. announced today that dosing has begun in an exploratory study of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 400mg QD in combination with ribavirin (RBV), with 0, 4, 8, or 12 weeks of pegylated interferon alfa 2a (Peg-IFN) in treatment-naive patients infected with HCV genotype 2 or 3.
› Verified 4 days ago
Dr. Andrew Wankier, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 95 White Sage Ave Ste C, Delta, UT 84624 Phone: 435-864-2551 | |
Dustin Kunz, Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 95 White Sage Ave Ste C, Delta, UT 84624 Phone: 435-864-2551 Fax: 435-864-3573 | |
Dr. Louis Howard Quackenbush Ii, D.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 95 White Sage Ave, Suite C, Delta, UT 84624 Phone: 435-864-2551 Fax: 435-864-3573 | |
Mr. Randy Dale Stinson, D.P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 95 White Sage Ave Ste C, Delta, UT 84624 Phone: 435-864-2551 Fax: 435-864-3573 | |
Mr. Chad Rand Crafts, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 95 White Sage Ave, Delta, UT 84624 Phone: 435-864-2551 Fax: 435-864-3573 |